Follow the people · Insider
Lawrence A. Kenyon
Lawrence A. Kenyon files insider transactions with the SEC as a chief financial officer of Outlook Therapeutics (OTLK). We hold 1 disclosed purchase or sale filed since 27 January 2006, 1 of them in the last 90 days.
- Files forOTLK
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure14 August 2026
Positions held
6 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 7 February 2019 — 14 August 2026Chief Financial Officer · Outlook Therapeutics (OTLK)14 Form 4 lines · source: SEC Form 4
- Filed 21 December 2016 — 18 September 2018CEO, Pres, CFO, Treas & Secy · Oncobiologics (ONS)4 Form 4 lines · source: SEC Form 4
- Filed 24 February 2014 — 24 February 2014Chief Financial Officer · Arno Therapeutics (ARNI)1 Form 4 line · source: SEC Form 4
- Filed 16 January 2007 — 23 July 2012President, CEO and CFO · Tamir Biotechnology (ACEL)8 Form 4 lines · source: SEC Form 4
- Filed 8 January 2009 — 2 August 2010EVP, Chief Financial Officer · Par Pharmaceutical Companies (PRX)27 Form 4 lines · source: SEC Form 4
- Filed 25 January 2006 — 25 January 2006CFO and Secretary · Neopharm (NEOL)1 Form 4 line · source: SEC Form 4
Everything they disclosed
55 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 101,010 shares of Outlook TherapeuticsSEC Form 414 August 2026Common Stock · traded 14 August 2026 · filed 14 August 2026
- ▲ bought on the open market 101,010 shares of Outlook Therapeutics (a derivative holding)SEC Form 414 August 2026Warrants (right to buy) · traded 14 August 2026 · filed 14 August 2026
- was granted 210,078 shares of Outlook Therapeutics (a derivative holding)SEC Form 423 July 2026Stock Option (Right to Buy) · traded 21 July 2026 · filed 23 July 2026
- ▲ bought on the open market 5,000 shares of Outlook TherapeuticsSEC Form 430 September 2024Common Stock · traded 26 September 2024 · filed 30 September 2024
- was granted 12,500 shares of Outlook Therapeutics (a derivative holding)SEC Form 422 March 2024Stock Option (Right to Buy) · traded 20 March 2024 · filed 22 March 2024
- ▲ bought on the open market 10,000 shares of Outlook TherapeuticsSEC Form 420 April 2021Common Stock · traded 20 April 2021 · filed 20 April 2021
- was granted 3,668,984 shares of Outlook Therapeutics (a derivative holding)SEC Form 45 October 2020Stock Option (Right to Buy) · traded 1 October 2020 · filed 5 October 2020
- was granted 450,000 shares of Outlook Therapeutics (a derivative holding)SEC Form 421 July 2020Stock Option (Right to Buy) · traded 17 July 2020 · filed 21 July 2020
- was granted 216,435 shares of Outlook Therapeutics (a derivative holding)SEC Form 420 March 2020Stock Option (Right to Buy) · traded 19 March 2020 · filed 20 March 2020
- ▼ sold on the open market 1,350 shares of Outlook TherapeuticsSEC Form 415 October 2019Common Stock · traded 18 September 2019 · filed 15 October 2019
- ▼ sold on the open market 1,350 shares of Outlook TherapeuticsSEC Form 423 September 2019Common Stock · traded 18 September 2019 · filed 23 September 2019
- was granted 450,000 shares of Outlook Therapeutics (a derivative holding)SEC Form 413 September 2019Stock Option (Right to Buy) · traded 12 September 2019 · filed 13 September 2019
- was granted 800,000 shares of Outlook Therapeutics (a derivative holding)SEC Form 419 February 2019Stock Option (Right to Buy) · traded 19 February 2019 · filed 19 February 2019
- ▲ bought on the open market 25,000 shares of Outlook TherapeuticsSEC Form 48 February 2019Common Stock · traded 7 February 2019 · filed 8 February 2019
- ▼ sold on the open market 10,100 shares of OncobiologicsSEC Form 418 September 2018Common Stock · traded 18 September 2018 · filed 18 September 2018
- was granted 500,000 shares of Oncobiologics (a derivative holding)SEC Form 43 August 2018Stock Option (Right to Buy) · traded 1 August 2018 · filed 3 August 2018
- ▼ sold on the open market 26,165 shares of OncobiologicsSEC Form 426 December 2017Common Stock · traded 22 December 2017 · filed 26 December 2017
- was granted 50,000 shares of OncobiologicsSEC Form 422 December 2016Common Stock · traded 21 December 2016 · filed 22 December 2016
- was granted 223,445 shares of Arno Therapeutics (a derivative holding)SEC Form 426 February 2014Stock Option (right to buy) · traded 24 February 2014 · filed 26 February 2014
- was granted 400,000 shares of Tamir Biotechnology (a derivative holding)SEC Form 425 July 2012Common Stock (Right to Buy) · traded 23 July 2012 · filed 25 July 2012
- had shares withheld for tax on 6,312 shares of Par Pharmaceutical CompaniesSEC Form 44 August 2010Common Stock · traded 2 August 2010 · filed 4 August 2010
- exercised options over 21,439 shares of Par Pharmaceutical Companies (a derivative holding)SEC Form 43 March 2010Common Stock, Option to Buy · traded 3 March 2010 · filed 3 March 2010
- exercised options over 21,439 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 3,261 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 700 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 4,711 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 500 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 2,800 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 2,700 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 100 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 100 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 1,041 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 200 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 200 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 3,426 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 100 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 100 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 600 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 400 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 300 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- ▼ sold on the open market 200 shares of Par Pharmaceutical CompaniesSEC Form 43 March 2010Common Stock · traded 3 March 2010 · filed 3 March 2010
- had shares withheld for tax on 897 shares of Par Pharmaceutical CompaniesSEC Form 412 January 2010Common Stock · traded 8 January 2010 · filed 12 January 2010
- was granted 21,653 shares of Par Pharmaceutical Companies (a derivative holding)SEC Form 48 January 2010Common Stock, Option to Buy · traded 4 January 2010 · filed 8 January 2010
- was granted 21,653 shares of Par Pharmaceutical Companies (a derivative holding)SEC Form 46 January 2010Common Stock, Option to Buy · traded 4 January 2010 · filed 6 January 2010
- was granted 10,826 shares of Par Pharmaceutical CompaniesSEC Form 46 January 2010Common Stock · traded 4 January 2010 · filed 6 January 2010
- was granted 85,758 shares of Par Pharmaceutical Companies (a derivative holding)SEC Form 412 January 2009Common Stock, Option to Buy · traded 8 January 2009 · filed 12 January 2009
- was granted 10,720 shares of Par Pharmaceutical CompaniesSEC Form 412 January 2009Common Stock · traded 8 January 2009 · filed 12 January 2009
- ▲ bought on the open market 2,828 shares of AlfacellSEC Form 412 April 2007Common Stock · traded 11 April 2007 · filed 12 April 2007
- ▲ bought on the open market 1,372 shares of AlfacellSEC Form 412 April 2007Common Stock · traded 11 April 2007 · filed 12 April 2007
- ▲ bought on the open market 1,100 shares of AlfacellSEC Form 412 April 2007Common Stock · traded 11 April 2007 · filed 12 April 2007
- ▲ bought on the open market 2,500 shares of AlfacellSEC Form 412 April 2007Common Stock · traded 11 April 2007 · filed 12 April 2007
- ▲ bought on the open market 4,997 shares of AlfacellSEC Form 412 April 2007Common Stock · traded 11 April 2007 · filed 12 April 2007
- ▲ bought on the open market 12,203 shares of AlfacellSEC Form 412 April 2007Common Stock · traded 11 April 2007 · filed 12 April 2007
- was granted 375,000 shares of Alfacell (a derivative holding)SEC Form 418 January 2007Common Stock (right to buy) · traded 16 January 2007 · filed 18 January 2007
- was granted 25,000 shares of Neopharm (a derivative holding)SEC Form 427 January 2006Stock Option (right to buy) · traded 25 January 2006 · filed 27 January 2006
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.